Insights+: EMA Marketing Authorization of New Drugs in June 2023

Shots:The EMA approved 7 New Chemical Entity (NCE) and 4 Biologic Drugs in June 2023, leading to treatments for patients and advances in the healthcare industryIn June 2023, the major highlights drugs were Jardiance approval for CKD patients, Briumvi (ublituximab-xiiy) for relapsing forms of multiple sclerosisPharmaShots has compiled a list of a…

BySenior EditorJuly 28, 2023

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in March 2023

Shots:The EMA approved 4 New Chemical Entity (NCE) and 5 Biologic Drugs in March 2023, leading to treatments for patients and advances in the healthcare industryIn March 2023, the major highlights drugs were Reblozyl’s Approval for anemia in adult patients with non-transfusion-dependent beta thalassemia, Pombiliti for late-onset pompe diseasePharmaShots has compiled a…

BySenior EditorApril 27, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in December 2022

Shots:The US FDA approved 8 NDAs and 5 BLA in December 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 86 novel products in 2022In December 2022, the major highlights drugs were Krazati (adagrasib) approval for non-small cell lung cancer with a KRASG12C mutation, Sunlenca…

BySenior EditorJanuary 18, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in February 2021

The US FDA has approved 7 NDAs and 1 BLA in Feb 2021, leading to treatments for patients and advances in the health care industry.The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 12 novel products in 2021.Additionally, last year in 2020, the US…

BySenior EditorMarch 18, 2021

Insights+: EMA Marketing Authorization of New Drugs in June 2023

Insights+: EMA Marketing Authorization of New Drugs in March 2023

Insights+: The US FDA New Drug Approvals in December 2022

Insights+: The US FDA New Drug Approvals in February 2021

Contact US

OUR INFORMATION

FOLLOW US